

RESEARCH ARTICLE

Defining Key Signaling Nodes and Therapeutic Biomarkers in NF1-Mutant Cancers

Clare F. Malone^{1,2}, Jody A. Fromm^{1,2}, Ophélia Maertens^{1,2}, Thomas DeRaedt^{1,2,3}, Rachel Ingraham^{1,2}, and Karen Cichowski^{1,2,3}

ABSTRACT

NF1 encodes a RAS GTPase-activating protein. Accordingly, aberrant RAS activation underlies the pathogenesis of *NF1*-mutant cancers. Nevertheless, it is unclear which RAS pathway components represent optimal therapeutic targets. Here, we identify mTORC1 as the key PI3K effector in *NF1*-mutant nervous system malignancies and conversely show that mTORC2 and AKT are dispensable. However, we find that tumor regression requires sustained inhibition of both mTORC1 and MEK. Transcriptional profiling studies were therefore used to establish a signature of effective mTORC1-MEK inhibition *in vivo*. We unexpectedly found that the glucose transporter GLUT1 was potently suppressed, but only when both pathways were inhibited. Moreover, unlike *VHL*- and *LKB1*-mutant cancers, reduction of ¹⁸F-FDG uptake required the suppression of both mTORC1 and MEK. Together, these studies identify optimal and suboptimal therapeutic targets in *NF1*-mutant malignancies and define a noninvasive means of measuring combined mTORC1-MEK inhibition *in vivo*, which can be readily incorporated into clinical trials.

SIGNIFICANCE: This work demonstrates that mTORC1 and MEK are key therapeutic targets in *NF1*-mutant cancers and establishes a noninvasive biomarker of effective, combined target inhibition that can be evaluated in clinical trials. *Cancer Discov*; 4(9); 1062–73. ©2014 AACR.

Authors' Affiliations: ¹Genetics Division, Department of Medicine, Brigham and Women's Hospital; ²Harvard Medical School; and ³Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, Massachusetts


Note: Supplementary data for this article are available at *Cancer Discovery* Online (<http://cancerdiscovery.aacrjournals.org/>).

C.F. Malone and J.A. Fromm share first authorship and contributed equally to this article.

Corresponding Author: Karen Cichowski, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, NRB 458C, Boston, MA 02115. Phone: 617-525-4722; Fax: 617-525-5801; E-mail: kcichowski@rics.bwh.harvard.edu

doi: 10.1158/2159-8290.CD-14-0159

©2014 American Association for Cancer Research.



INTRODUCTION

The *NF1* tumor suppressor is mutated or suppressed in a variety of sporadic cancers, including glioblastoma, neuroblastoma, melanoma, and non-small cell lung cancer (1–5). *NF1* mutations also underlie the familial cancer syndrome neurofibromatosis type 1 (*NF1*; refs. 6 and 7). Patients with *NF1* exhibit a variety of tumorigenic and nontumorigenic manifestations, but the most common cause of death is malignant peripheral nerve sheath tumors (MPNST). These highly aggressive tumors are lethal in approximately 70% of patients, and conventional chemotherapy and radiation do not reduce mortality in individuals with inoperable tumors (8–10). Therefore, developing effective targeted therapies for these individuals represents an important and unmet clinical need. Moreover, an effective therapy for this tumor type may be more broadly applicable to other sporadic *NF1*-mutant cancers.

The *NF1* tumor suppressor gene encodes a RAS GTPase-activating protein (GAP), which inactivates RAS by catalyzing the hydrolysis of RAS-GTP (6, 7). As such, when *NF1* is mutated or suppressed, RAS and downstream effectors become hyperactivated (11). Both the PI3K-mTOR and MEK-ERK pathways have been shown to be important in various *NF1*-mutant tumors, and therefore components of these pathways represent potential therapeutic targets (12–15). However, given the plethora of available drugs that

target these pathways, we set out to genetically and chemically deconstruct the most important signaling nodes in *NF1*-mutant MPNSTs. Together with preclinical studies in a genetically engineered mouse tumor model, we found that mTOR complex 1 (mTORC1) is the key PI3K pathway component in these *NF1*-mutant malignancies, AKT and mTORC2 are dispensable, and only sustained mTORC1 and MEK inhibition promotes tumor regression.

Several combined PI3K-MEK pathway trials are in development or are being considered for other cancers (16). However, the clinical challenge will be to identify a drug combination and dose that effectively suppresses both pathways, while minimizing toxicity. It is currently unclear how dosing can be adjusted while confirming that both targets are sufficiently inhibited in real time, especially given that the duration of inhibition seems to be an important determinant of efficacy. Thus, establishing a tractable biomarker for effective, combined target inhibition would greatly facilitate this effort. By performing transcriptional profiling and imaging studies, we unexpectedly identified *GLUT1*, which mediates ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) uptake, as a key gene that is suppressed before tumor regression but only when both pathways are effectively inhibited. Moreover, we show that ¹⁸F-FDG uptake is a reliable readout of combined target inhibition. This insight can be directly applied to the design of clinical trials in *NF1*-mutant cancers and may also have broader utility in other RAS-driven tumors.




Figure 1. p110 α and mTORC1 are critical for the proliferation of NF1-deficient tumor cells. **A**, S462, 90-8TL, and LN-229 cells were transfected with pooled siRNAs targeting PIK3CA, PIK3CB, PIK3CD, or nontargeting siRNA. Bar graphs, relative change in cell number from day 0 to 96 hours as compared with control cells transfected with the nontargeting siRNA. Data points, triplicate averages \pm SD. Immunoblots depict p110 α , p110 β , and p110 δ protein levels 72 hours after transfection with the indicated siRNA. Actin serves as a loading control. *, $P < 0.002$. **B**, immunoblots showing pAKT and pS6 levels in S462 cells following treatment with indicated inhibitors (4 hours; 500 nmol/L). AKT, S6, and actin serve as controls. **C**, bar graphs of S462 and 90-8TL cells treated inhibitors as specified. Numbers represent the relative change in cell number from day 0 to 96 hours as compared with vehicle-treated control cells. Data points, triplicate averages \pm SD. *, $P < 0.04$. (continued on following page)

RESULTS

p110 α and mTORC1 Are the Key Effectors in NF1-Mutant Nervous System Malignancies

We have previously shown that loss or inactivation of *NF1* triggers the aberrant activation of PI3K-mTORC1 signaling in human and mouse MPNSTs (17). However, it is currently unclear which specific components within this pathway represent the best therapeutic targets. Such insight would reveal which drugs should be preferentially evaluated or excluded in clinical trials. Therefore, we sought to genetically and chemically deconstruct this pathway in *NF1*-mutant MPNSTs. There are three class 1A catalytic PI3K isoforms: p110 α , p110 β , and p110 δ . Although p110 α is frequently mutated in human cancer, p110 β has been shown to play an essential role in *PTEN*-mutant cancers, and p110 δ is critical in chronic lymphocytic leukemia (18–20). To identify which catalytic isoforms are essential in *NF1*-mutant nervous system malignancies, we first assessed the biologic effects of isoform-specific ablation in human MPNST cells derived from patients with NF1. Although all three isoforms were present in MPNSTs, genetic ablation of p110 α , but not p110 β or p110 δ , dramatically impaired the proliferation of

both tumor lines (Fig. 1A). Similarly, *NF1*-mutant glioblastoma (GBM) cells were exclusively sensitive to siRNA-mediated depletion of p110 α , but not p110 β or p110 δ , suggesting that p110 α may play a more general role in *NF1*-deficient cancers (Fig. 1A). To complement these findings, we used PI3K isoform-specific inhibitors: the p110 α -specific inhibitor A66-(S), the p110 β -specific inhibitor AZD-6284, and the p110 δ -specific inhibitor CAL-101, as well as GDC-0941, a pan-PI3K inhibitor (21–24). The reported specificities of each drug are outlined in Supplementary Table S1. In human MPNST cell lines, the p110 α -specific inhibitor A66-(S) and GDC-0941 potently inhibited the phosphorylation of AKT and S6; however, the p110 β - or p110 δ -specific inhibitors, AZD-6284 and CAL-101, respectively, did not suppress the phosphorylation of either protein (Fig. 1B). Accordingly, A66-(S) was the only isoform-specific inhibitor that suppressed proliferation in these cells ($P = 0.039$ in 90-8TLs and $P = 0.0006$ in S462s; Fig. 1C). Together, these observations suggest that p110 α is the primary catalytic subunit responsible for proproliferative PI3K signaling in *NF1*-mutant nervous system malignancies.

mTOR functions in two distinct complexes: the rapamycin-sensitive complex mTORC1, which phosphorylates 4E-BP1




Figure 1. (Continued) **D**, S462 and 90-8TL cells were transfected with pooled siRNAs targeting *MTOR*, *RAPTOR*, *RICTOR*, or nontargeting siRNA. Bar graphs, relative change in cell number from day 0 to 96 hours as compared with control cells transfected with the nontargeting siRNA. Data points, triplicate averages \pm SD. Immunoblots show mTOR, Raptor, Rictor, pAKT, and pS6 levels 72 hours after transfection with the indicated siRNA. AKT, S6, and actin levels serve as controls. *, $P < 0.02$. **E**, S462 cells were treated with the rapamycin (Rap) at 100 nmol/L, Torin1 at 250 nmol/L, or MK-2206 (concentration indicated). Bar graph, relative change in cell number from day 0 to 96 hours as compared with vehicle-treated control cells. Data points, triplicate averages \pm SD. Immunoblots show pAKT^{T308}, pAKT^{S473}, pTSC2^{T1462}, pS6, and 4E-BP1 levels in the presence of the specified inhibitors. AKT, TSC2, S6, and actin serve as controls. *, $P < 0.0001$. **F**, S462 cells treated with either rapamycin at 100 nmol/L, MK-2206 at 5 μ mol/L, or both drugs together. Bar graphs, relative change in cell number from day 0 to 96 hours as compared with vehicle-treated control cells. Data points, triplicate averages \pm SD. p, phosphorylated.

and S6 kinase, and the relatively rapamycin-insensitive complex mTORC2, which phosphorylates AKT at serine 473 (25, 26). *NF1*-deficient MPNSTs have been shown to be sensitive to rapamycin, indicating that mTORC1 plays a role in this tumor type; however, the contribution of mTORC2 activity, if any, to MPNST growth is unknown (13, 17). We genetically targeted essential component proteins of each complex to evaluate the relative contribution of these two complexes. RAPTOR is an essential component of mTORC1, but is not present in mTORC2, whereas RICTOR, a primary component protein of mTORC2, is not a member of the mTORC1 complex (27, 28). As expected, siRNA-mediated loss of RAPTOR or mTOR suppressed S6 phosphorylation and led to impaired proliferation of MPNST cell lines (Fig. 1D). However, loss of RICTOR had no effect on MPNST proliferation, despite the effective suppression of phosphorylation of the mTORC2 target AKT (Fig. 1D).

To further evaluate a role, or lack thereof, for AKT, tumors cells were treated with the allosteric AKT inhibitor MK-2206 (29). MK-2206 suppressed the phosphorylation of AKT at S473 and T308 and effectively inhibited AKT kinase activity, as confirmed by the loss of TSC2 phosphorylation on T1462 (Fig. 1E and Supplementary Fig. S1). However, unlike

rapamycin, MK-2206 had no effect on the proliferation of *NF1*-mutant MPNST cells (Fig. 1E). The mTOR kinase inhibitor Torin1 inhibits both the mTORC1 and mTORC2 complexes. Notably, Torin1 has been reported to more effectively inhibit mTORC1, as compared with rapamycin, and in particular more potently suppresses 4E-BP1 phosphorylation, as observed in these studies (Fig. 1E and Supplementary Fig. S1). Accordingly, Torin1 potently suppressed the proliferation of *NF1*-mutant cells and did so better than rapamycin ($P < 0.02$). As noted, both MK-2206 and Torin1 equivalently and potently suppressed AKT phosphorylation and activity, although only Torin1 suppressed MPNST cell proliferation. Moreover, MK-2206 did not enhance the antiproliferative effects of rapamycin (Fig. 1F). Taken together, these results suggest that mTORC1 is a critical effector in *NF1*-mutant cancers and that mTORC2 and AKT are dispensable in these tumor cells.

Selection of an Effective PI3K-mTOR Pathway Inhibitor

These *in vitro* studies suggested that pan-PI3K inhibitors, p110 α -specific inhibitors, or mTORC1 inhibitors should suppress the growth of *NF1*-mutant MPNSTs. Therefore, we first




Figure 2. Therapeutic effects of PI3K and MEK pathway inhibitors *in vivo*. **A**, waterfall plot depicting change in tumor volume in NPCis mice after 10 days of treatment with vehicle (black), GDC-0941 (blue), or rapamycin (green). The left y-axis indicates the log₂ of the fold change in volume after 10 days. The right y-axis indicates the percent change in tumor volume relative to day 0. **B**, pAKT/pS6/4E-BP1 immunoblots of tissue from animals exposed to GDC-0941 or rapamycin for the indicated amount of time. AKT, S6, and vinculin serve as controls. **C**, waterfall plot depicting change in tumor volume after 10 days of treatment with PD-0325901 (yellow) or rapamycin and PD-0325901 (Rap-PD) in combination (purple). Vehicle and rapamycin (gray) are reprinted from **A** for reference. The left y-axis indicates the log₂ of the fold change in volume after 10 days. The right y-axis indicates the percent change in tumor volume relative to day 0. **D**, immunoblots showing pERK levels in tissue after treatment with PD-0325901 once daily (top) or twice daily (bottom). Hours, number of hours from initial treatment. Representative samples from three biologic replicates are shown. Vinculin and ERK serve as controls. **E**, waterfall plot depicting change in tumor volume after 10 days of treatment with PD-0325901 twice daily or PD-0325901 twice daily in combination with rapamycin. The left y-axis indicates the log₂ of the fold change in tumor volume relative to day 0 and the right y-axis indicates the percent change in tumor volume.

evaluated the *in vivo* effects of GDC-0941 and rapamycin on a genetically engineered mouse MPNST model. Like human MPNSTs, tumors from these animals harbor compound mutations in *Nf1* and *Trp53* and develop with an average latency of 5 months. These MPNSTs are highly aggressive, and mice survive for an average of 10.7 days after tumors are detected, thus recapitulating the aggressive nature of human tumors (30). As previously shown, rapamycin suppressed the growth of *Nf1*/*Trp53*-mutant MPNSTs ($P < 0.0001$; ref. 13); however, GDC-0941 did so significantly less well ($P = 0.0021$; Fig. 2A). Notably, the MTD of GDC-0941 (150 mg/kg) inhibited the

phosphorylation of AKT, S6, and 4E-BP1 in tumors within 1 hour; however, these pathways were reactivated within 4 hours after treatment (Fig. 2B). In contrast, rapamycin suppressed S6 and 4E-BP1 phosphorylation for at least 18 hours, consistent with the observed enhanced efficacy and the demonstrated importance of mTORC1 in these tumors. It should be noted that AKT is not activated by relief of feedback mechanisms in this model, as we have previously shown (Fig. 2B; ref. 13, 31). Several other PI3K-mTOR pathway inhibitors, including BEZ-235, Torin2, and INK-128, were evaluated in these animals (data not shown); however,

we were unable to identify an inhibitor that exhibited better pharmacodynamics or growth inhibition than rapamycin at tolerable doses in these animals. Therefore, rapamycin was selected for further studies.

Combined, Sustained Inhibition of mTORC1 and MEK Promotes MPNST Regression *In Vivo*

Although mTORC1 is a critical signaling node in *NF1*-mutant tumors, mTORC1 inhibition exerted only cytostatic effects on MPNSTs *in vitro* and *in vivo* (Figs. 1D and E and 2A; ref. 13). Therefore, we evaluated the effects of rapamycin combined with a MEK inhibitor, which targets a second critical RAS-effector pathway. Tumor-bearing mice were treated with vehicle, the MEK inhibitor PD-0325901, rapamycin, or the combination of rapamycin and PD-0325901. As a monotherapy, PD-0325901 slightly attenuated the growth of MPNSTs, but did so less than rapamycin (Fig. 2C). However, combined PD-0325901 and rapamycin induced tumor regression in these mice (Fig. 2C). Interestingly, these observations differ from effects observed in benign *NF1*-deficient peripheral nervous system tumors and myeloid malignancies, where MEK seems to function as the dominant RAS-effector pathway and MEK inhibitors exert cytotoxic effects alone, suggesting that different tumor types harboring the same initial driving genetic lesion may rely on different downstream signals (32, 33). Nevertheless, upon examining the pharmacodynamics of PD-0325901 at this dose, we found that ERK phosphorylation was inhibited for only 4 to 6 hours, whereas sustained inhibition could be achieved by dosing with PD-0325901 twice daily (Fig. 2D). As such, we hypothesized that a revised dosing schedule might exert more potent therapeutic effects. Twice-daily PD-0325901 treatment did not promote tumor regression as a monotherapy; however, when combined with rapamycin, twice-daily PD-0325901 treatment improved the therapeutic response (Fig. 2E). All mice treated with this combination responded, and more than half of the tumors regressed 50% or more, with several shrinking 75% or more. Together, these observations indicate that the duration of both MEK and mTORC1 inhibition is a critical determinant of the therapeutic response.

Identifying GLUT1 as a Component of the Therapeutic Signature That Is Suppressed before Tumor Regression

Pharmacodynamic markers in tumors are often not examined during clinical trials, and when they are, the kinetics of suppression are difficult to evaluate. Therefore, if a treatment does not show efficacy, especially in cases of dose escalation, it is often unclear whether the target or targets were sufficiently inhibited. Therefore, we sought to identify a molecular change that might serve as a functional biomarker of effective, combined inhibition of mTORC1 and MEK pathways. The transcriptional profiles of tumors from animals treated with vehicle, rapamycin, PD-0325901 (twice daily), or the combination of rapamycin and PD-0325901 were evaluated. Importantly, tissues were collected after 14 hours of treatment: a time point that would capture transcriptional changes caused by sustained target inhibition but occurring before tumor regression. Using a gene expression class com-

parison, we identified a gene set that was exclusively regulated by combined rapamycin and PD-0325901 treatment (Fig. 3A). Interestingly, *Slc2a1*, which encodes a glucose transporter and is commonly referred to as *Glut1*, was identified as one of the uniquely suppressed genes in rapamycin-PD-0325901-treated tumors (Fig. 3A). Effective mTORC1 and MEK target inhibition in tumor tissue was verified (Fig. 3B). qPCR analysis confirmed that *Glut1* levels were reduced 64% after only 14 hours of treatment compared with vehicle-treated tumors and that neither rapamycin nor PD-0325901 exerted suppressive effects alone (Fig. 3C). A dramatic decrease in GLUT1 protein levels was further confirmed by evaluating its expression in tumor biopsies taken before and 3 days after treatment (Fig. 3D). These findings differ from observations in *VHL*- and *LKB1*-mutant tumors, where GLUT1 mRNA and consequently protein expression are primarily regulated by mTOR and HIF1 α , and its expression can be suppressed by mTORC1 inhibitors alone (34, 35). However, in these *Nf1*-mutant MPNSTs, suppression of both mTORC1 and the MEK-ERK pathways is required. This finding resolves a long-standing observation that rapamycin is not sufficient to suppress the expression of GLUT1 or other HIF1 α target genes *in vitro* or *in vivo* in this tumor type (13). Together, these results demonstrate that GLUT1 is suppressed in MPNSTs only after combined mTORC1 and MEK inhibition, which could be exploited for developing an imaging biomarker of combined target inhibition.

Only Combined, Effective Suppression of mTORC1 and MEK Inhibits ^{18}F -FDG Uptake

GLUT1 is a membrane-bound glucose transporter that is frequently overexpressed in tumors, in part because altered tumor metabolism requires increased glucose uptake (36–39). This metabolic activity can be measured by PET scans designed to quantify ^{18}F -FDG uptake (40). GLUT1 has been shown to regulate ^{18}F -FDG uptake in a variety of tumor types (41, 42). MPNSTs are generally FDG-PET positive, and enhanced ^{18}F -FDG uptake is used to diagnose a conversion to malignancy, as MPNSTs often arise from benign precursor lesions (43). Because human MPNSTs exhibit a strong FDG-PET signal, and because GLUT1 was specifically suppressed in tumors treated with combined rapamycin and PD-0325901, we hypothesized that the substantial reduction in GLUT1 mRNA and protein might inhibit ^{18}F -FDG uptake in these tumors. To evaluate this possibility, FDG-PET imaging was performed on tumor-bearing mice. As expected, MPNSTs were FDG-PET positive at baseline, mirroring the behavior of human MPNSTs (Fig. 4A). Mice were then treated with vehicle, PD-0325901, rapamycin, or PD-0325901-rapamycin, and PET analysis was performed a second time, 40 hours after the baseline scan. This time point was selected because it represents a time before detectable regression occurs, to avoid any confounding change in the FDG-PET signal due to a reduction in tumor size. It should be noted that the initial (64%) decrease in *Glut1* mRNA levels can be detected 14 hours after treatment; however, given the dramatic decrease in GLUT1 protein after 72 hours, this repression is sustained and perhaps enhanced. Animals treated with vehicle, PD-0325901, or rapamycin did not have a significant change in ^{18}F -FDG uptake after treatment (Fig. 4A and B); however, animals




Figure 3. GLUT1 is an early biomarker of effective combined MEK-mTORC1 inhibition. **A**, microarray analysis of mouse tumors 14 hours after treatment with vehicle, rapamycin, PD-0325901 (PD), or both rapamycin and PD-0325901 (Rap-PD). Heatmap depicts the uniquely upregulated genes (dark blue) or downregulated genes (light blue) from tumors in mice treated with Rap-PD as compared with all other groups reaching a significance level of $P = 0.001$. The arrow denotes *Slc2a1* (encoding GLUT1), highlighted in red, as one gene of particular interest within this signature. **B**, immunoblot of pERK and 4E-BP1 levels in individual tumors as described in **A**. ERK and GAPDH serve as a control. **C**, quantitative PCR showing *Slc2a1* transcript levels in individual tumors described in **A**. **D**, immunoblot showing GLUT1 levels in a pretreatment biopsy sample, and in the same tumor after treatment with PD-0325901 (twice daily) and rapamycin. p120 serves as a control.

treated with both PD-0325901 and rapamycin exhibited a significant decrease in the highest standardized uptake value (SUV_{max} ; $P < 0.004$; Fig. 4A and B). Importantly, although hexokinase and other GLUT genes can regulate glucose uptake in some settings (41, 44–46), rapamycin-PD-0325901 treatment did not affect the expression of any of these genes, suggesting that GLUT1 may be the rate-limiting step for FDG-PET uptake in MPNSTs (Supplementary Table S2).

These observations suggested that FDG-PET imaging could be used as a biomarker of effective combined mTORC1-MEK inhibition in *NF1*-mutant tumors. Such a biomarker would be invaluable in the course of evaluating similar therapies in the clinic and in the course of dose de-escalation/escalation studies. This biomarker would be particularly useful if the early changes in FDG-PET imaging were predictive of a later change in tumor size. To experimentally evaluate this possibility, we performed a dose de-escalation study in mice. Mice were treated with rapamycin

in combination with 100%, 50%, or 25% of the PD-0325901 dose. As expected, this produced a range of responses in FDG-PET uptake at 40 hours and tumor regression after 10 days (Fig. 4C and D). Importantly, the suppression of FDG-PET activity at 40 hours, as measured by change in SUV_{max} correlated with the ultimate decrease in tumor size after 10 days (Pearson $r = 0.711$; $P = 0.03$; Fig. 4D and E). These results suggest that early changes in the FDG-PET signal are indicative of the degree of target inhibition and correlate with eventual tumor regression in MPNSTs treated with combined mTORC1-MEK inhibitors.

DISCUSSION

Numerous PI3K pathway inhibitors have been developed and are being evaluated in clinical trials (16). However, in many cancers, it is not clear which specific components within this pathway are most critical or to what degree they




Figure 4. ^{18}F -FDG uptake is a noninvasive biomarker of combined MEK-mTORC1 inhibition. **A**, representative images of FDG-PET scans of animals treated with vehicle, PD-0325901, rapamycin, or both (Rap-PD). PD-0325901 was dosed twice daily. Baseline scans are shown at left (pre-), and the right image shows the same view of the same animal 40 hours after treatment with the indicated compound (post-). Arrow, MPNST. Scale bar, relative ^{18}F -FDG uptake, with low uptake in blue and highest uptake in white. **B**, the ^{18}F -FDG uptake by tumors was quantified using SUV_{\max} , and the \log_2 of the fold change of this number was calculated to indicate the change in ^{18}F -FDG uptake 40 hours after treatment relative to baseline for each animal. The change in combination-treated animals (Rap-PD) is compared with monotherapy and vehicle-treated animals (controls). The y-axis indicates the \log_2 of the fold change in SUV_{\max} relative to baseline. **C**, representative images of FDG-PET scans of animals treated with 100% PD-0325901-rapamycin, 50%PD-0325901-rapamycin, or 25% PD-0325901-rapamycin. The left image (pre-) shows the baseline scan for each animal and the right (post-) shows the scan 40 hours after treatment with the indicated dose. Again, the tumors are indicated with arrows. Scale bar, relative FDG uptake, with low uptake in blue and highest uptake in white. **D**, left, a waterfall plot depicting the \log_2 fold change of SUV_{\max} , a quantification of tumor FDG-PET activity, of selected tumors at 40 hours after treatment with PD-0325901 (25%, 50%, or 100% of the dose) and rapamycin. Right, a waterfall plot depicting the \log_2 of fold change in tumor volume of the same mice after 10 days. Individual tumors are graphed in the same order on each plot. **E**, regression analysis of nine combination-treated mice (100%, $n = 3$; 50%, $n = 3$; 25%, $n = 3$). The x-axis represents the \log_2 of fold change in tumor volume at 10 days, and the y-axis represents the \log_2 of fold change in SUV_{\max} levels after 40 hours of treatment. Both numbers are relative to day 0 measurements. Line, best-fit linear correlation, and the Pearson coefficient (r) was calculated.

must be inhibited. Such information would undoubtedly facilitate the selection of the most appropriate drugs for clinical studies. In this study, we used a genetic and chemical approach to systematically deconstruct the PI3K signaling pathway in *NF1*-mutant nervous system malignancies. Importantly, we found that mTORC1, which is regulated by p110 α in these tumors, is the minimal, essential PI3K path-

way component, and that surprisingly AKT and mTORC2 are dispensable. However, although agents that inhibit mTORC1 promote cytostasis in human tumor cells and genetically engineered models, tumor regression requires concomitant suppression of the MEK-ERK pathway.

Notably, there are currently no effective therapies for MPNSTs. As such, these studies reveal a promising therapeutic

RESEARCH ARTICLE

Malone et al.

approach as well as a mechanistic framework for selecting the most appropriate agents for clinical trials. For example, because p110 β does not seem to contribute to the therapeutic response in these tumors, perhaps p110 α -specific, β -sparing PI3K inhibitors could be used with less toxicity (47). Alternatively, because mTORC1 seems to be the key PI3K effector in these tumors, perhaps rapalogues, which exhibit excellent pharmacokinetic properties, may be suitable for combination therapies. The observation that AKT is not activated in these tumors by feedback inhibition, and that AKT inhibitors do not enhance the effects of rapamycin, further alleviates the concern that AKT suppression may be required in this setting. Nevertheless, these studies suggest that successful agents must promote sustained inhibition of both ERK and mTORC1. Importantly, suppression of these same targets results in tumor regression in a mouse model of *NF1*-mutant melanoma, underscoring the importance of these pathways in *NF1*-deficient cancers (4). Nevertheless, establishing the sufficient degree/length of inhibition of both targets that will be required to mediate an efficacious response in patients represents a formidable challenge.

Although mouse models are useful for identifying critical therapeutic targets in genetically defined cancers, the ultimate success of a therapy in humans depends on many factors. Certainly, species-specific differences in tumor complexity may limit efficacy or restrict therapeutic responses to a subset of patients. However, perhaps an even more important consideration relates to dosing. One of the primary obstacles in developing combination therapies, especially when targeting two major signaling pathways, is achieving efficacy while preventing toxicity. As such, even if the correct therapeutic targets have been identified, it may not be possible to sufficiently suppress these targets in humans. MEK inhibitors have been shown to exhibit toxicity in humans at high doses (48, 49). Therefore, in this study, we used a dose of PD-0325901 that is comparable with the tolerable dose in humans. Similarly, the dose of rapamycin was selected based on a previous preclinical study that led to a successful human clinical trial in a number of tuberous sclerosis complex-related pathologies, although reported trough plasma levels were somewhat higher than what has been observed in humans (~50 ng/mL vs. 3–20 ng/mL in humans; refs. 50–53). However, our preliminary observations suggest that lower doses and/or intermittent dosing of mTOR inhibitors/rapalogues are also effective when combined with MEK inhibitors. Given the differences in toxicity observed between mice and humans, only clinical trials will reveal whether an effective, nontoxic dose can be achieved. As such, another important goal of this study was to develop a biomarker that could be used to guide dosing in the clinic.

Current clinical trial strategies involve dosing up to the MTD of one drug, and adding the second drug to the tolerable dose when possible. However, it is not always clear how dose escalation/de-escalation affects the degree or kinetics of target inhibition or if dosing at the MTD is necessary. As such, we set out to identify a biomarker that would serve as an early downstream readout of effective, combined inhibition of MEK and TORC1. Although several genes were identified in these tumors, *GLUT1* stood out as an important and tractable molecular change. Consistent with the

documented role of GLUT1 in regulating glucose uptake, we found that ^{18}F -FDG uptake, as measured by FDG-PET, was a reliable readout of effective, combined target inhibition *in vivo*. Importantly, changes in GLUT1 expression and ^{18}F -FDG uptake occurred before tumor regression, supporting its role as a molecular marker of TORC1-MEK suppression rather than a consequence of tumor shrinkage. Interestingly, neither GLUT1 expression nor glucose uptake was suppressed after treatment with either rapamycin or MEK inhibitors alone. This observation differs from findings in a subset of other mTOR-driven tumor types, where HIF1 α -dependent *GLUT1* expression is decreased after treatment with rapamycin, as is ^{18}F -FDG uptake (34, 35). We have previously shown that neither GLUT1 nor HIF1 α levels are altered in MPNSTs when treated with rapamycin, marking an important distinction between *NF1*-deficient tumors and these other mTOR-driven tumors (13). Here, we provide an explanation for this difference, as simultaneous inhibition of both the mTORC1 and MEK is required to suppress GLUT1 and ^{18}F -FDG uptake in MPNSTs. It will be interesting to determine whether inhibition of both pathways is required to alter glucose uptake in other tumors, in particular other RAS-driven tumors. Certainly, other factors, such as hexokinase activity or other members of the GLUT family, may contribute to glucose uptake in some cancers, and in these instances, ^{18}F -FDG uptake might not be an effective biomarker. However, our studies suggest that FDG-PET imaging represents a promising, noninvasive means of measuring combined mTORC1-MEK inhibition *in vivo* in these *NF1*-mutant tumors, which can be readily incorporated into clinical trials. Such a tool should help identify the most effective drugs and facilitate dosing, and its utility may extend beyond *NF1*-mutant cancers.

METHODS

Cell Lines and Reagents

S462 and LN229 cells were purchased from the ATCC. The 90-8TL cells were generously provided by Dr. Eric Legius (KU Leuven, Belgium). The authors performed no further authentication of the cell lines. Cell lines were cultured in DMEM supplemented with FBS (10%) and L-glutamine. Antibodies were obtained from the following sources: Cell Signaling Technologies: pAKT (4060), AKT (9272), pERK (4370), ERK (9102), pS6 (2211), S6 (2217), p110 α (4255), p110 β (3011), Vinculin (4650), 4E-BP1 (9452), mTOR (7C10), Rictor (53A2), Raptor (24C12), pTSC2 (3611), TSC2 (3612), GAPDH (2118); Santa Cruz Biotechnology: p110 β (sc-7176); Trans Labs: p120 (G12920); Sigma: Actin (A2066); Alpha Diagnostics: Glut1 (GT11-A). Torin1, A66-(S), AZD-6284, and CAL-101 were kindly provided by Nathaniel Gray (Dana-Farber Cancer Institute/Harvard Medical School). MK-2206 was generously provided by D. Wade Clapp (Indiana University, Indianapolis, IN). GDC-0941 was provided by Genentech. PD-0325901 was a gift from Kevin Shannon (University of California, San Francisco, CA). Rapamycin was purchased from LC Laboratories.

RNAi

Nontargeting and *PIK3CA*, *PIK3CB*, *PIK3CD*, *RAPTOR*, *RICTOR*, and *MTOR* siRNA pools were purchased from Dharmacon (D-001810-10, L-003018-00, L-003019-00, L-006775-00, L-004107-00, L-016984-00, L-003008-00, respectively). siRNAs were transfected overnight in antibiotic-free medium using RNAiMax lipofectamine from Invitrogen.

Cellular Proliferation Studies

Approximately 125,000 cells per well were seeded in 6-well plates. For siRNA experiments, cells were seeded 12 to 16 hours after transfection. Twenty-four hours after plating, day 0 counts were taken using a hemocytometer and trypan blue exclusion. For inhibitor experiments, drug treatments were started at this time. Inhibitors were changed once daily, except in PI3K isoform experiments, where drugs were replenished twice daily. Final cell counts were taken 96 hours after day 0 counts.

Drug Treatments and Dosing Schedule

Animal procedures were approved by the Center for Animal and Comparative Medicine in Harvard Medical School in accordance with the NIH Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act. C56/BL6 NPcis mice have been previously described (30). Mice were treated daily with rapamycin via i.p. injections at 5 mg/kg, which were prepared as previously described (13). PD-0325901 was administered at 1.5 mg/kg once or twice daily (10 hours apart) by oral gavage. PD-0325901 was prepared as previously described (54). GDC-0941 was administered at 150 mg/kg once daily by oral gavage. GDC-0941 was prepared as previously described (55). Compounds given in combination were administered sequentially.

Biopsy

Tumor biopsy was performed on mice before drug treatment using the wedge biopsy technique and snap-frozen. Drug treatment was started 8 hours after initial biopsy. The posttreatment biopsy was performed 3 days after treatment began. The mouse was anesthetized by isoflurane inhalation and given a local block with lidocaine and marcaine while the tumor biopsy was collected.

Tumor Volume Measurements

Mice were started on a treatment when tumor size reached 200 to 1,000 mm³. Tumor size was measured every 2 to 3 days by Vernier calipers. Tumor volume was calculated using the standard formula $L \times W^2 \times 0.52$. A mouse pathologist confirmed that all tumors in this study are MPNSTs.

¹⁸F-FDG-PET Imaging and Analysis

PET/CT scans were performed on the Bioscan NanoPET/CT at the Longwood Small Animal Imaging Facility. This PET scanner is equipped with a dedicated isoflurane anesthesia system, temperature-controlled platform, cardiac gating, and respiratory gating. PET scanning was performed on anesthetized animals lying motionless on a table, after retro-orbital i.v. injection of 0.1 to 10 mCi of ¹⁸F-FDG PET radioisotope, while being imaged with a coincidence camera. The mice were imaged after a predetermined "washout" period (30–60 minutes). Individual mice were first scanned before treatment and then 40 hours after the treatment regimen was initiated (see dosing schedule methods). For quantitative analysis, the SUV normalized to body weight in the tumor was calculated using $SUV = ACvoi (kBq/mL)/[FDGdose (MBq)/BW (kg)]$, where ACvoi is the average activity concentration in the tumor volume (or the maximum value), FDGdose is the dose of ¹⁸F-FDG administered, and BW is the body weight. For evaluating tumors, the highest SUV in the tumor was taken as the SUV_{max}.

Microarray

RNA isolated from MPNST tumor samples from NPcis mice treated for 14 hours with vehicle, rapamycin, PD-0325901, or the combination of rapamycin and PD-0325901. For all PD-0325901-treated samples, PD-0325901 was dosed a second time at 10 hours. RNA was isolated with Trizol following the manufacturer's protocol. RNA

clean-up was then performed using the Qiagen RNeasy Kit (#74104). The Partners HealthCare Center for Personalized Genetic Medicine core facility hybridized the RNA to the Affymetrix Mouse Gene 1.0 STS. To determine genes differentially expressed in the combination treatment, a class comparison between the combination-treated samples and all other samples was performed. Analysis was completed using BRB-Array tools developed by Dr. Richard Simon (National Cancer Institute, NIH, Rockville, MD) and the BRB-ArrayTools Development team. Thresholds were set at $P < 0.001$. Microarray data can be accessed in the GEO database (accession number GSE57141).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: C.F. Malone, J.A. Fromm, T. DeRaedt, K. Cichowski

Development of methodology: C.F. Malone, T. DeRaedt

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): C.F. Malone, J.A. Fromm, O. Maertens, T. DeRaedt, R. Ingraham, K. Cichowski

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C.F. Malone, J.A. Fromm, O. Maertens, T. DeRaedt, K. Cichowski

Writing, review, and/or revision of the manuscript: C.F. Malone, J.A. Fromm, K. Cichowski

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): C.F. Malone, J.A. Fromm, R. Ingraham

Study supervision: K. Cichowski

Acknowledgments

The authors thank Haley Goodwill, John Frangioni, and the Longwood Small Animal Imaging facility at Beth Israel Hospital for performing the ¹⁸F-FDG-PET imaging studies. They also thank Roderick T. Bronson (Harvard Medical School, Boston, MA) for histologic confirmation of all MPNSTs.

Grant Support

This work was supported by a grant from the NCI (5R01CA111754-08, to K. Cichowski), the Department of Defense (W81XWH-13-1-0044, to K. Cichowski), the Children's Tumor Foundation (CTF; to K. Cichowski), and the Ludwig Center at Dana-Farber/Harvard Cancer Center (to K. Cichowski). C.F. Malone was supported, in part, by the Pharmacological Sciences Training Program Grant from the NIH (T32 GM007306). J.A. Fromm was supported by the CTF.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received February 14, 2014; revised May 16, 2014; accepted June 2, 2014; published OnlineFirst June 9, 2014.

REFERENCES

- Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008;321:1807–12.
- McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. *Cancer Cell* 2009;16:44–54.
- The I, Murthy AE, Hannigan GE, Jacoby LB, Menon AG, Gusella JF, et al. Neurofibromatosis type 1 gene mutations in neuroblastoma. *Nat Genet* 1993;3:62–6.

RESEARCH ARTICLE

Malone et al.

4. Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, et al. Elucidating distinct roles for NF1 in melanomagenesis. *Cancer Discov* 2013;3:338–49.
5. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* 2008;455:1069–75.
6. Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. *Cell* 1990;63:843–9.
7. Cawthon RM, Weiss R, Xu GF, Viskochil D, Culver M, Stevens J, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. *Cell* 1990;62:193–201.
8. Zehou O, Fabre E, Zelek L, Sbidian E, Ortonne N, Banu E, et al. Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. *Orphanet J Rare Dis* 2013;8:127.
9. Evans DGR, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. *J Med Genet* 2002;39:311–4.
10. Porter DE, Prasad V, Foster L, Dall GF, Birch R, Grimer RJ. Survival in malignant peripheral nerve sheath tumours: a comparison between sporadic and neurofibromatosis type 1-associated tumours. *Sarcoma* 2009;2009:756395.
11. DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC, et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. *Cell* 1992;69:265–73.
12. See WL, Tan I-L, Mukherjee J, Nicolaides T, Pieper RO. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. *Cancer Res* 2012;72:3350–9.
13. Johannessen CM, Johnson BW, Williams SMG, Chan AW, Reczek EE, Lynch RC, et al. TORC1 is essential for NF1-associated malignancies. *Curr Biol* 2008;18:56–62.
14. Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, et al. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. *Clin Cancer Res* 2013;19:450–61.
15. Parkin B, Ouillette P, Wang Y, Liu Y, Wright W, Roulston D, et al. NF1 inactivation in adult acute myelogenous leukemia. *Clin Cancer Res* 2010;16:4135–47.
16. Britten CD. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. *Cancer Chemother Pharmacol* 2013;71:1395–409.
17. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. *Proc Natl Acad Sci U S A* 2005;102:8573–8.
18. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. *Science* 2004;304:554.
19. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. *Nature* 2008;454:776–9.
20. Herman SEM, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. *Blood* 2010;116:2078–88.
21. Jamieson S, Flanagan JU, Kolekar S, Buchanan C, Kendall JD, Lee W-J, et al. A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. *Biochem J* 2011;438:53–62.
22. Lannutti BJ, Meadows SA, Herman SEM, Kashishian A, Steiner B, Johnson AJ, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. *Blood* 2011;117:591–4.
23. Nylander S, Kull B, Björkman JA, Ulvinge JC, Oakes N, Emanuelsson BM, et al. Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. *J Thromb Haemost* 2012;10:2127–36.
24. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. *J Med Chem* 2008;51:S522–32.
25. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. *Mol Cell* 2002;10:457–68.
26. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science* 2005;307:1098–101.
27. Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. *Biochem Soc Trans* 2009;37:217–22.
28. Sarbassov DD, Ali SM, Kim D-H, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. *Curr Biol* 2004;14:1296–302.
29. Hirai H, Sootoome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. *Mol Cancer Ther* 2010;9:1956–67.
30. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, et al. Mouse models of tumor development in neurofibromatosis type 1. *Science* 1999;286:2172–6.
31. De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. *Cancer Cell* 2011;20:400–13.
32. Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. *J Clin Invest* 2013;123:340–7.
33. Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, et al. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. *J Clin Invest* 2013;123:335–9.
34. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. *Nat Med* 2006;12:122–7.
35. Shackelford DB, Vasquez DS, Corbeil J, Wu S, Leblanc M, Wu C-L, et al. mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. *Proc Natl Acad Sci U S A* 2009;106:11137–42.
36. Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, et al. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. *Am J Pathol* 2009;174:1544–52.
37. Younes M, Ertan A, Lechago LV, Somoano J, Lechago J. Human erythrocyte glucose transporter (Glut1) is immunohistochemically detected as a late event during malignant progression in Barrett's metaplasia. *Cancer Epidemiol Biomarkers Prev* 1997;6:303–5.
38. Sakashita M, Aoyama N, Minami R, Maekawa S, Kuroda K, Shirasaka D, et al. Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. *Eur J Cancer* 2001;37:204–9.
39. Grover-McKay M, Walsh SA, Seftor EA, Thomas PA, Hendrix MJ. Role for glucose transporter 1 protein in human breast cancer. *Pathol Oncol Res* 1998;4:115–20.
40. Som P, Atkins HL, Bandopadhyay D, Fowler JS, MacGregor RR, Matsui K, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. *J Nucl Med* 1980;21:670–5.
41. Smith TA. The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation. *Nucl Med Biol* 2001;28:1–4.
42. Avril N. GLUT1 expression in tissue and (18)F-FDG uptake. *J Nucl Med* 2004;45:930–2.
43. Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, et al. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. *Cancer* 2010;116:451–8.

44. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. *Cancer* 1997;80:1046–51.
45. Ito T, Noguchi Y, Satoh S, Hayashi H, Inayama Y, Kitamura H. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. *Mod Pathol* 1998;11:437–43.
46. Aloj L, Caracó C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. *Cancer Res* 1999;59:4709–14.
47. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. *Nat Rev Drug Discov* 2009;8:627–44.
48. LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. *Clin Cancer Res* 2010;16:1924–37.
49. Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL. Ocular toxicity of targeted therapies. *J Clin Oncol* 2012;30:3277–86.
50. Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. *J Neurosci* 2008;28:5422–32.
51. Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. *Ann Neurol* 2013;74:679–87.
52. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet* 2013;381:125–32.
53. Ando K, Kurihara M, Kataoka H, Ueyama M, Togo S, Sato T, et al. The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. *Respir Investig* 2013;51:175–83.
54. Brown AP, Carlson TCG, Loi C-M, Graziano MJ. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. *Cancer Chemother Pharmacol* 2007;59:671–9.
55. Wallin JJ, Guan J, Prior WW, Lee LB, Berry L, Belmont LD, et al. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo. *Clin Cancer Res* 2012;18:3901–11.

CANCER DISCOVERY

Defining Key Signaling Nodes and Therapeutic Biomarkers in NF1-Mutant Cancers

Clare F. Malone, Jody A. Fromm, Ophélia Maertens, et al.

Cancer Discovery 2014;4:1062-1073. Published OnlineFirst June 9, 2014.

Updated version Access the most recent version of this article at:
doi:10.1158/2159-8290.CD-14-0159

Supplementary Material Access the most recent supplemental material at:
<http://cancerdiscovery.aacrjournals.org/content/suppl/2014/06/10/2159-8290.CD-14-0159.DC1.html>

Cited Articles This article cites by 55 articles, 21 of which you can access for free at:
<http://cancerdiscovery.aacrjournals.org/content/4/9/1062.full.html#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts related to this article or journal.](#)

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.